Akshata IjantkarSenior Scientist at Bristol Myers Squibb
Akshata Ijantkar is a Senior Scientist at Bristol Myers Squibb, Seattle. She is the Analytical CMC lead for Autologous and Allogenic gene-edited programs. Her areas of expertise include statistics, assay design, analytical strategy, cell, and gene therapy. She was part of the product development team that led Breyanzi from process lock, IND, INDa, BLA, and post BLA/ commercial activities. Akshata has six years of experience in cell therapy and eight years of experience in analytical development. Before joining Juno Therapeutics (later acquired by Celgene + Bristol Myers Squibb) Akshata worked as a Flow Cytometry Scientist at Pfizer, Dept of Vaccine Therapeutics.